U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C29H30FN3O.ClH
Molecular Weight 492.027
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Flezelastine hydrochloride

SMILES

Cl.FC1=CC=C(CC2=NN(C3CCCN(CCC4=CC=CC=C4)CC3)C(=O)C5=C2C=CC=C5)C=C1

InChI

InChIKey=KBNISKYDAJMVNI-UHFFFAOYSA-N
InChI=1S/C29H30FN3O.ClH/c30-24-14-12-23(13-15-24)21-28-26-10-4-5-11-27(26)29(34)33(31-28)25-9-6-18-32(20-17-25)19-16-22-7-2-1-3-8-22;/h1-5,7-8,10-15,25H,6,9,16-21H2;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C29H30FN3O
Molecular Weight 455.5664
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

FLEZELASTINE, a phthalazinone derivative, an anti-asthmatic/anti-allergic agent. It exhibits inhibition of histamine release and 5-lipoxygenase, calcium antagonistic properties and antagonism at the histamine H1 receptor. FLEZELASTINE is a racemate consisting of (+)- and (-)-enantiomers. Both enantiomers contribute to the pharmacodynamic efficacy of racemic flezelastine.

Originator

Approval Year

PubMed

Substance Class Chemical
Record UNII
7DAMTNUI2A
Record Status Validated (UNII)
Record Version